Patent protections for the pharmaceutical companies have been among the most controversial aspects of recent high-profile trade agreements such as the Canada-EU Trade Agreement (CETA) and the Trans-Pacific Partnership (TPP). CETA would require Canada to extend the term of protection for patents through a patent term restoration rule, which the Conservative government acknowledged would add billions to provincial health-care costs. The TPP would reinforce those reforms, requiring changes even if CETA falls through.
Enter your email address to
register a free account.